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 Introduction 
 The excitement of clinical science was first made apparent to 
me through the somewhat theatrical medium of the medical 
‘grand round’. In the 1980s, at both Hammersmith Hospital 
and Oxford, where I undertook postgraduate training, the 
format was in its heyday. A junior doctor would present the 
history and clinical and investigative features of a patient with 
a puzzling illness. This was followed by a scholarly dissection 
of the key issues by the presenter, after which the chair and a 
distinguished audience would subject the arguments to forensic 
dissection. Not infrequently, ongoing research in laboratories 
within the hospital had actually generated new knowledge 
directly relevant to the patient and the audience would hear of 
these discoveries for the first time. It was a powerful vehicle for 
conveying the thrill of clinical science. It was, moreover, a form 
of discourse that William Harvey would have understood well. 
In endowing this lecture, he stipulated that the orator should 
‘exhort the Fellows and Members of this College to search and 
study out the secrets of nature by way of experiment’. 1 In the 
17th century, non-invasive forms of medical science were limited 
in scope. Anatomical dissection was the principal tool and, 
of necessity, the only patients who could be subjected to that 
form of examination were those no longer alive. In his notes 
for the Lumleian Lectures, Harvey reminded himself ‘Not to 
praise or dispraise other anatomists, for all did well, and there 
was some excuse even for those who are in error’. 1 That kind 
exhortation might bring a wry smile to those who remember the 
Hammersmith Hospital rounds of the 1980s, where impassioned 
clashes between the giants of medicine gathered there made the 
atmosphere more ‘Grand Guignol’ than ‘grand round’. 
 So, in homage to the tradition of the grand rounds, I will 
start this lecture with a description of a patient, whom I will 
call M, a 43-year-old woman who attends the diabetes clinic 
at Addenbrooke’s Hospital. Having lost touch with us a few 
years ago, she was re-referred by her GP because she had blood 
glucose levels that were persistently high. When she came to 
see me, she smiled resignedly, saying ‘my insulin isn’t working 
again’. Over several visits, the truth about M’s diabetes gradually 
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emerged. She had been obese from early childhood, leading to 
severe bullying at school. Having struggled with her obesity 
throughout her teens and early twenties, in her late twenties she 
suddenly lost a lot of weight, which delighted her. However, the 
weight loss was actually due to the fact that she had developed 
type 2 diabetes and was now losing a large number of calories in 
her urine. After several years of oral medication, she eventually 
needed insulin treatment to control her blood glucose. However, 
she noticed that whenever she controlled her diabetes tightly, 
her weight piled back on. So she solved this problem by having 
‘holidays’; periods of many months when she would omit 
her insulin and ‘let her diabetes rip’ before having enough of 
the extreme fatigue, nocturia and thrush. Doctors telling her 
that she was developing the microvascular complications of 
sustained hyperglycaemia, including retinopathy, neuropathy 
and nephropathy, had little impact because these issues didn’t 
bother her in the moment and, like many people, she was too 
preoccupied with her immediate life stresses to think much 
about the future. If we cannot help M move from her current 
metabolic trajectory, there is a strong likelihood that she will 
become blind, dialysis dependent and/or lose a limb well 
before the normal retirement age. Although her type 2 diabetes 
occurred unusually early for a person of European descent, her 
story is not at all atypical in other ethnicities, many of whom 
suffer a disproportionately higher burden of diabetes than 
white Europeans. The International Diabetes Federation (IDF) 
predicts that the number of people with diabetes will rise from 
an estimated 415 million in 2015 to 642 million in 2040, 2 mostly 
in settings without adequate resources to detect complications 
early and intervene to reduce later disability. 
 In order to fully understand the conditions that have led to 
M’s plight, we need to better understand the environmental 
drivers of the current obesity epidemic, of which she is but one 
of many millions of victims. But that will not be enough. We 
need to know what it is that made M so susceptible to becoming 
obese and at such a young age and why, while many people with 
lifelong severe obesity remain normoglycaemic, in her case just 
a couple of decades of over-nutrition has been enough to lead 
her to develop type 2 diabetes. 
 The causes of obesity 
 Why has obesity become more common? 
 Obesity is not a new disease. The Palaeolithic sculptor of 
the Venus of Willendorf (Fig  1 ), working about 25,000 years 
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ago, cannot have rendered the shape of a very obese female 
so perfectly from imagination alone. Hippocrates himself 
reported that obese people more frequently died suddenly and 
recommended that ‘they should eat only once a day and take 
no baths and sleep on a hard bed and walk naked as long as 
possible’. 3 In 1727, the British physician Thomas Short wrote 
‘No age has seen more instances of corpulency than our own’. 3 
Nonetheless, it is clear that obesity has become considerably 
more common in the vast majority of developed and developing 
countries since the beginning of the last century, with a 
particular acceleration appearing to start around the 1980s in 
highly developed countries such as the USA. 4 
 As the mass of any object can only increase if the energy put 
into it is greater than the energy lost from it, then attention has 
obviously been paid to changes in the environment that acted to 
promote caloric ingestion and those that have acted to diminish 
the expenditure of energy. In brief, until about the past 50 years, 
never in the course of history have the majority of humans 
had such continuous access to sufficient ingestible calories at a 
time when they did not require a large expenditure of energy to 
acquire them. There are many powerful influences that together 
have acted to encourage caloric intake. 
 Ingestible calories are cheaper than ever before in human 
history. The percentage of household income spent on food 
has progressively decreased in all developed and developing 
countries over the past century, much of this decrease being 
attributable to advances in food production, packaging, 
refrigeration and transport. 5 For instance, in the USA the 
proportion of household income spent on food fell from about 
50% to about 12% between the late 19th and the late 20th 
centuries. 5 In the UK, the average household spend on food and 
drink has also fallen, currently being 11.1% of all household 
expenditure. 6 Ingestible calories have been made more desirable 
and attractive through food advertising, higher sugar and fat 
content, and a sophisticated industry that has cleverly used 
sensory science to encourage purchase and consumption 
of food. What is presented as a ‘standard’ portion has risen 
dramatically in size over a relatively short period. 7 Calories are 
more ubiquitously and continually available. There are many 
more shops selling food, 8 which is also now freely available in 
non-traditional outlets that are often open all hours. There has 
been a relative increase in the availability of cheap, processed, 
calorie-dense food, which tends to be less satiating owing 
to lower concentrations of protein, fibre and slowly digested 
carbohydrates than non-processed food, while there has been 
a growing price gap, with unprocessed foods with higher 
concentration of protein and fibre becoming consistently more 
expensive than processed foods high in sugar and fat. 9 
 These changes have occurred at the same time as the 
requirements for the use of energy to support physical activity 
(at work or domestically) have diminished, 10 and when the 
widespread increase in domestic central heating means that 
the demands for thermogenesis for maintenance of body 
temperature have decreased. 11 It is not particularly surprising 
that a state where energy intake chronically exceeds energy 
expenditure is now commonplace. 
 An interesting idea that is emerging, but is as yet unproven, 
is that over-nutrition in early life somehow sets a long-term 
trajectory influencing levels of adult adiposity. 12 Other 
hypotheses implicating factors such as environmental 
chemicals including antibiotics, perhaps acting through 
changes in the human microbiome, currently remain in the 
realms of speculation. 13 Before any public health efforts based 
on these ideas are launched, such hypotheses will need to 
be tested rigorously and repeatedly with full consideration 
of the confounding effects of genetic background and other 
environmental and socio-economic influences. 
 Why are some people resistant to the obesogenic 
environment while some are susceptible? 
 In the face of these major environmental stresses, why is it that 
many people are still lean? It is possible, of course, that all of 
those who remain lean are making conscious choices to restrain 
their food intake and increase their expenditure to obtain the 
social, economic and health benefits that leanness brings. It 
is also possible that those who are resistant to the obesogenic 
environment are somehow different in their biological makeup. 
So, a somewhat tongue-in-cheek question is the following: 
are lean people ‘morally superior’ or are they ‘biologically 
different’? Of course, few things in biology are black and white 
and it is likely that both biological predisposition and conscious 
exertion of choice both impact on a person’s state of adiposity at 
any particular time. 
 One way of providing a quantitative estimate of the impact of 
inherent biological (genetically encoded) factors is to compare 
the degree of similarity between identical (monozygotic) twin 
pairs who share 100% of their genetic makeup, with non-
identical (dizygotic) twin pairs who share only 50%. Both types 
of pair largely share similar pre- and postnatal environments. 
This type of study can lead to estimates of the influence that 
shared genes, shared environment and non-shared environment 
have on the inter-individual variance of any human trait. 
Multiple independent studies of this type have clearly shown 
that genetic factors dominate, with some studies reporting that 
up to as much as 70% of the population variance in body mass 
index (BMI) or related measures of adiposity is attributable 
to inherited factors. 14 In a remarkable study, an American 
psychiatrist, Mickey Stunkard, studied Scandinavian twins who 
 Fig 1.  Venus of Willendorf . Palaeolithic carving in oolitic limestone from 
about 25,000 BCE. Wellcome Library, London. 
CMJv16n6-Harveian.indd   552 19/11/16   1:25 PM
Harveian Oration 2016
© Royal College of Physicians 2016. All rights reserved. 553
had been adopted by different families shortly after birth. 15 In 
adult life, the adiposity of these adopted children was not at all 
correlated with the adiposity of their adoptive parents or the 
siblings who they grew up with. But it was remarkably strongly 
correlated with that of the twin they had been separated from. 
This was particularly striking (intra-pair correlation coefficient 
of about 0.7) when the twins raised apart were identical and 
less so when non-identical, where the correlation coefficient 
was around about 0.3. These estimates are supported by recent 
advances allowing single nucleotide polymorphism (SNP)-
based heritability estimates among unrelated individuals with 
genome-wide genotyping. Such approaches also highlight a 
major contribution of common genetic variation underlying 
variation in BMI. 16 Thus, a compelling and consistent body 
of data indicates that genetic factors play a major role in 
determining an individual’s position along the population 
distribution of adiposity. 
 I have, I confess, created a somewhat false dichotomy, 
implying that adiposity could only be influenced by ‘conscious 
choice’ or ‘biological factors’. This is over-simplistic. A wealth 
of evidence is emerging that demonstrates the powerful 
impact of environmental factors which exploit the fact that, 
as recently summarised by Theresa Marteau and colleagues, 
‘much human behaviour is automatic, cued by environmental 
stimuli, resulting in actions that are largely unaccompanied by 
conscious reflection’. 17 
 What physiological processes are these genes likely to 
be impacting on? 
 As genes act through physical rather than metaphysical means, 
it behoves us to ask whether and how body fat stores are 
regulated by the organism, and what are the signals used to 
govern such regulatory processes? In this regard, what we now 
know about human biology is indebted to decades of careful 
and insightful work in animal models, largely rodents. This 
work has revealed the existence of two broad classes of signal 
that influence appetite and energy expenditure; namely, longer-
term signals that convey information about stored energy 
reserve (mostly triglyceride in adipose tissue) and shorter-
term signals that provide information about the amount and 
composition of ingested macronutrients. 
 Pathways that sense nutritional stores 
 Experiments in rodents undertaken in the 1940s and 1950s 
by scientists such as Adolph, 18 Kennedy, 19 Hetherington 20 and 
Anand 21 first established that nutritional stores were under 
some sort of homeostatic control and that a functioning 
hypothalamus was a necessary component of that process. The 
latter had in fact been first suggested by clinical reports at the 
turn of the 19th and 20th centuries by German physicians such 
as Frohlich, Mohr and Babinski. 3 
 Arguably, the modern era of obesity science began in 
1959 with a publication by GR Hervey, from the Medical 
Research Council Department of Experimental Medicine in 
Cambridge, 22 which demonstrated the existence of a circulating 
factor influencing eating behaviour and body fat stores. Hervey 
created a partial surgical union of skin and subcutaneous 
tissues between pairs of genetically identical rats, establishing 
a permanent circulatory connection between the two across 
which blood-borne signals could equilibrate. One member 
of each parabiotic pair was then subjected to a hypothalamic 
lesion that made it overeat and become obese. Remarkably, 
those rats parabiosed to such a partner rapidly reduced their 
food intake and became markedly undernourished. 
 In Hervey’s own words:
 the experiments demonstrate what in a normal single animal 
would constitute a feedback system. The results also imply that 
the information reaches the hypothalamus in some form which is 
capable of crossing through the parabiotic union . 22 
 In the 1970s, studying genetically obese strains of mice 
previously described by the Jackson Laboratories, 23,24 Coleman 
used the technique of parabiosis to prove that the ob/ob mouse 
was lacking a blood-borne signal to which the db/db mouse was 
completely unresponsive. 25,26 
 It took, however, a further 20 years and the power of murine 
molecular genetics before Friedman and colleagues at the 
Rockefeller University in New York discovered that this 
blood-borne signal was a cytokine-like hormone, which they 
termed leptin. This new hormone is produced exclusively 
in fat cells and its secretion is proportionate to increases in 
adipose tissue mass. 27,28 Leptin interacts with receptors in the 
hypothalamus and elsewhere in the brain to reduce food intake 
and increase energy expenditure; thus, remarkably, this most 
unprepossessing of cell types, the adipocyte, turned out to 
be an ‘intelligent’ member of the neuroendocrine signalling 
community, participating directly in providing information 
to the brain about the state of nutrient stores. Leptin plays a 
major (perhaps its principal) role in the signalling of states of 
nutritional depletion to the brain, with many – if not all – of 
the neuroendocrine responses to starvation being critically 
dependent on the brain sensing a decrement in circulating 
leptin. 29 The discovery of leptin was a major milestone in the 
history of physiology, and the work of Friedman and Coleman 
(sadly now deceased) that led to its discovery has been widely 
recognised by major international prizes. 
 Much subsequent science has been stimulated by the 
exploration of the downstream cellular and molecular 
pathways mediating these effects. The arcuate nucleus in 
the mediobasal hypothalamus is a major site for leptin 
action. 30 There, it acts on two key populations of neurons 
whose profile of neuropeptide expression is unique to this 
tiny and highly specific anatomical site. Neurons expressing 
pro-opiomelanocortin (POMC) are stimulated by leptin, 
and the products of the POMC gene, such as alpha and beta 
melanocyte-stimulating hormone (MSH), are powerful 
suppressors of appetite and stimulate energy expenditure 
through activation of the sympathetic nervous system. 31,32 
Reciprocally, a population of neurons expressing neuropeptide 
Y (NPY) and agouti-related peptide (AGRP) are rapidly 
switched off by leptin, 33 consistent with the fact that NPY is a 
powerful appetite stimulant and AGRP is an antagonist of MSH 
peptides. 34 The power of these tiny populations of neurons 
(there are around 800 AGRP-expressing neurons in a murine 
brain that contains about 75 million neurons) is illustrated by 
the remarkable finding that an adult mouse in which the AGRP-
positive neurons are acutely ablated through a transgenic toxin 
approach will continue to behave otherwise normally but ceases 
eating completely and will, if permitted, starve itself to death. 35 
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It has recently been recognised that hypothalamic neurons 
concerned with leptin sensing and body weight regulation 
have particular electrophysiological properties that make them 
uniquely suited to the integration of incoming hormonal and 
neural signals over the medium to long term. 36 
 Pathways that sense ingested nutrients and alter meal 
termination 
 While the leptin–melanocortin signalling system informs 
the brain about long-term energy stores in adipose tissue, 
the brain also receives much more acute information about 
the size and macronutrient composition of individual 
meals. Such information is integrated with the longer-term 
adipostatic signals to influence the process of satiety, leading 
to meal termination. Cholecystokinin (CCK) was the classic 
postprandial hormone involved in satiety. Rodents given 
exogenous CCK eat smaller meals, but compensate by eating 
more frequently. 37 A growing body of research into cells of the 
entero-endocrine system, which are stimulated to release their 
contents by the presence of nutrients in the gastrointestinal 
tract, has demonstrated how important signals such as those 
derived from glucagon-like peptide 1 (GLP1), peptide YY 
(PYY) and ghrelin are in mediating the sense of postprandial 
satiety. 38–40 More recently, advances are being made in 
identifying signals that influence macronutrient choice. Thus, 
the liver-derived hormone FGF21 is potently induced by high 
carbohydrate loads and, acting through the hypothalamus, 
powerfully reduces preference for ingestion of carbohydrate 
versus other macronutrients. 41 
 The human dimension 
 The discovery of the leptin–melanocortin system in the 
mid-1990s generated great excitement, but the relevance of 
this system to human physiology and/or disease remained 
unknown. As a young endocrinologist, I had paid little 
attention to the field of body weight regulation, considering 
obesity (including my own!) to be largely the cosmetically 
unfortunate result of poor lifestyle choices. This changed in 
the early 1990s when, in my regular endocrine clinic, I saw a 
woman with a complex poly-endocrine syndrome, one feature 
of which was severe obesity from early childhood. We worked 
out that she was failing to cleave several hormonal precursors 
into mature peptide hormones 42 and eventually went on to 
pinpoint her disorder as being due to biallelic mutations in the 
neuroendocrine-specific subtilisin-like pro-protein convertase 
PCSK1, the first disorder of pro-protein processing to be 
described in a metazoan organism. 43 
 It seemed implausible to me that her obesity would be 
unrelated to her underlying genetic lesion. The corollary of 
this was that human beings could become severely obese 
owing to mutations in a single specific gene. Around the time 
of the first report of leptin, we heard of two severely obese and 
hyperphagic British first cousins from a consanguineous family 
of Pakistani origin. The human genomic sequence of leptin was 
not yet known, so we initially obtained subcutaneous adipose 
biopsies and sequenced the complementary DNA (cDNA) of 
these children. However, using the radiolabel- and gel-based 
methodologies of the day, we didn’t see a mutation. A year or so 
later, Sadaf Farooqi joined the lab as a clinical research fellow 
and, as her first foray into laboratory work, I suggested that she 
use newly validated assays for circulating leptin to examine the 
plasma of these children. There was none detectable. We pulled 
out the old sequencing films and, with a mix of excitement 
and horror, realised that at one point in the sequence in the 
normal control there was a tightly bunched run of six guanine 
nucleotides, but in the affected children there were only five. 
We had missed this the first time around. The children were 
homozygotes for a frameshift mutation that would truncate the 
leptin molecule. 44 
 Having only ever studied two obese pedigrees, we had found 
the genetic cause in both, representing the first humans for 
whom a clear single gene explanation for obesity had been 
established. 45 So, human beings could indeed become obese 
for purely biological reasons. How common was this? We 
reckoned that if a phenotype is due to a highly penetrant genetic 
mutation, it is likely to occur early in life and be severe, so we 
focused our attention on severe childhood obesity. Over the 
next few years we discovered several other genes, mutations in 
which cause obesity, including  MC4R 46 simultaneously with 
Froguel, 47 TRKB 48 and  BDNF . 49 The first mutations in  POMC , 50 
leptin receptor 51 and  SIM1 52 were reported by others. Our 
efforts in genetic discovery in childhood-onset obesity have 
continued to the present day under the scientific leadership of 
Sadaf Farooqi. 53,54 
 How did these genetic mutations lead to chronic energy 
imbalance? We carried out detailed phenotypic evaluation 
of children carrying these mutant genes. This clearly showed 
that the main driver for their obesity was a markedly increased 
appetite. Affected children had increased hunger and 
reduced duration of satiety, leading to increased food-seeking 
behaviour and diminished meal-related satiation. 48,55,56 This 
has been, in some cases, accompanied by a small reduction 
in energy expenditure per unit lean mass. 53,57 Thus, through 
the discovery and study of human genetic disorders, we 
established that a state of human obesity could be produced 
by a purely genetic route, with those mutations leading to a 
change in eating behaviour through impairing the function 
of brain circuits concerned with sensing nutrient stores. 
Therefore, these forms of obesity were not so much ‘metabolic’ 
as ‘neurobehavioural’, with the defective gene resulting in an 
aberrantly strong drive for what is, after all, a necessary human 
behaviour. 
 In one case, congenital deficiency of leptin (Fig  2 ), we have 
had the great privilege of witnessing the dramatic effects of 
correcting a genetic disorder by providing the missing gene 
product. 56,58 In all cases, the obesity of congenital leptin 
deficiency is completely reversible with leptin therapy, no 
matter how long the deficiency has been present. 59 Within a few 
days after initiation of leptin therapy, spontaneous food intake 
reduces by over 70% and this is accompanied by astonishing 
changes in higher brain centres, as exemplified by the blood-
flow changes to an area of the brain such as the ventral striatum 
in response to the visual presentation of food-related stimuli. 
This occurs before there is any discernible change in weight. 60 
The implications of such studies, demonstrating the power 
of a simple secreted protein coming only from adipose tissue 
to exert such powerful influences on a higher brain centre, is 
profound and counters the notion that, as far as human obesity 
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is concerned, we can readily separate (as Gordon Kennedy 
actually tried to do) 19 ‘hypothalamic’ (subconscious, not under 
voluntary control) from ‘higher’ (conscious, wholly controllable 
by free will) elements. 
 The importance of postprandially released endocrine signals 
in the control of human food intake and energy balance has 
been demonstrated not so much through genetics as through 
pharmacological studies. The administration of a variety of 
these gut-derived peptides in a manner that mimics what would 
happen after a meal has been repeatedly shown to have major 
effects on eating behaviour in humans. 38 
 Does this have any relevance to variation of adiposity 
in the general population and common forms of 
obesity? 
 Most obese humans do not harbour single mutations that, 
alone, cause their energy imbalance. However, adiposity is a 
highly heritable trait, so it should be possible to gain insights by 
looking in a hypothesis-free way at variation at the level of the 
whole genome in the broader population. Such studies, which 
represent a triumph of international collaboration, have been 
undertaken in a rigorous way so that the genetic determinants 
of adiposity have been systematically explored in hundreds of 
thousands of humans. Some scepticism has been expressed by 
the broader biomedical community about the value of these 
‘genome-wide association study (GWAS)’ approaches, as it has 
often proven challenging to establish beyond reasonable doubt 
what bioactive molecule is actually mediating the change in 
physiology and/or disease risk. Obesity is an excellent example 
of how GWAS approaches can provide a very important 
‘gestalt’ regarding the global genetic architecture of a complex 
trait. When one takes all the common genetic variants that 
reproducibly associate with measures of fatness in humans, 
and collectively look at the tissues and genes that these variants 
 Fig 2.  Child with congenital leptin defi ciency before (aged 3 years) and 
after (aged 7 years) leptin therapy . Modifi ed with permission from the An-
nual Review of Medicine 2005, volume 56, pp 443–58. © by Annual Reviews, 
 www.annualreviews.org 
are most likely to be impacting, the result is remarkable. 
The vast majority of human variants influencing fatness 
impact on genes that are most highly expressed in the brain. 61 
Additionally, many of the variants are close to genes encoding 
highly neuronally expressed molecules in which loss of function 
mutations have previously been described to cause monogenic 
obesity (eg  MC4R , 46 POMC 50 and  BDNF ). 49 
 The late Jane Wardle convincingly demonstrated that 
variants in these genes had a quantifiable impact on eating 
behaviour in normal children and, through those behaviours, 
significantly influenced a child’s risk of becoming obese. 14 It 
can now be unequivocally stated that, across many populations, 
an individual’s susceptibility to be either obese or lean is 
powerfully influenced by the chance events associated with the 
inheritance of particular variants of genes that are functioning 
predominantly in the central nervous system. Despite these 
unarguable findings, it has been hard to shift the concept of 
‘greed’ as a moral failing rather than a biological predisposition, 
and the increased appetite drive that predisposes many people 
to obesity is not infrequently linked in the public mind, and the 
popular press, with laziness and stupidity. 
 One markedly obese person who was neither lazy nor stupid 
was William Taft, the 27th president of the USA and the 10th 
chief justice of the US Supreme Court, the only person to hold 
both offices. At his heaviest, he weighed 340 lbs and had a 
BMI of over 46. Perusal of his diaries and those of members 
of his staff give a poignant picture of a man desperate to avoid 
the medical consequences of severe obesity, and making 
prodigious but only partially and intermittently successful 
efforts to control his weight. 62 The following is an abridged 
abstract from the diary of Ira Smith, Taft’s ‘chief of mails’ at 
the White House:
 The President dieted, all right, but not when he could escape 
supervision. I remember once when I accompanied him on a 
journey to Ohio. When we got on the train, leaving the doctor 
and Mrs. Taft behind, the President began to perk up. He also 
apparently began to think about food, although it was then ten 
o’clock in the evening … the President appeared at the door of 
his sitting room … I took one look and knew what was on his 
mind. 
 ‘Anybody seen the conductor?’ he asked. 
 The conductor came a-running. 
 ‘The dining car…’ Mr. Taft began shyly. ‘Could we get a snack?’ 
 The conductor looked surprised. ‘Why, Mr. President, there 
isn’t any dining car on this train.’ 
 The President’s sun-tanned face turned pink, with perhaps a 
few splashes of purple … 
‘ Norton!’ he called in a cold voice. ‘Mr. Norton!  ’[Norton was 
his private secretary]  …‘there is no diner on this train.’ 
 Norton … reminded Mr. Taft that they had had dinner at the 
White House, and assured him that they would not go without 
breakfast. He recalled that the President’s doctor had warned 
him about eating between meals. The President brushed him 
aside, turning back to the conductor. 
 ‘What’s the next stop, dammit?’ he asked. ‘The next stop where 
there’s a diner?’ 
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 The conductor believed that would be Harrisburg. Mr. Taft 
glared at Norton and addressed the conductor: 
 ‘I am President of the United States, and I want a diner 
attached to this train at Harrisburg. I want it well stocked with 
food, including filet mignon …’ He silenced the secretary’s 
protests with a roar. ‘What’s the use of being President,’ he 
demanded, ‘if you can’t have a train with a diner on it?’ 
 The appetite for food differs greatly between people in its 
intensity and ‘greed’ is not confined to the feckless. Obesity is 
not a new disease; nor is it particular to a social underclass. 
 Do these fi ndings have any direct relevance for patient 
care or public policy? 
 As a result of the genetic science undertaken over the past 
20 years, we can now give definitive diagnoses to many children 
who previously would have been labelled as having ‘simple 
obesity’, with all the pejorative implications regarding improper 
parental care that the term has traditionally carried. Some of these 
disorders are not uncommon. Melanocortin 4 receptor deficiency 
occurs in about 1 per 1,000 people, 63 making it commoner than 
other high-profile genetic diseases such as Duchenne muscular 
dystrophy or cystic fibrosis. The discovery that a child with severe 
obesity actually harbours a pathogenic mutation in a gene known 
to cause obesity is increasingly occurring in scenarios when there 
has been a previous or ongoing threat to take a child from the 
care of their parents. 54 In the rare case of leptin deficiency, leptin 
therapy is life-changing. 59 Unfortunately, because of the dose–
response curve of leptin, this hormone, while hugely effective in 
children with very low concentrations, is not efficacious (at least 
alone) in producing weight loss when leptin concentrations are in 
the normal or high range. 64 
 Gut-derived peptides are a major area of pharmaceutical 
activity. A long-acting form of GLP1 has been licensed as an 
obesity therapeutic. 65 It seems likely that much of the salutary 
effect of gastric bypass surgery on weight loss is mediated not, 
as is commonly and mistakenly thought, through restriction 
or malabsorption, but through the profound effects on the 
secretion of these postprandial hormones that occur secondary 
to alterations in the anatomy of the gut. 66 Forms of surgery that 
attempt to limit food intake by simply restrictive measures (such 
as gastric banding) have little or no impact on such hormonal 
milieu and poorly sustained efficacy. Much effort is ongoing to 
identify the precise nature of the hormonal perturbances that 
are mediating this effect and with the hope that multi-hormonal 
therapies will, in time, be able to replace bariatric surgery. 
 The fact that obesity-prone people are biologically predisposed 
to overeat provides ammunition to those who encourage public 
policies to reduce the factors within the environment that 
encourage excessive caloric ingestion. The road from scientific 
knowledge of the causes of obesity to the implementation of 
such knowledge in public health policy remains a twisting and 
precarious one, a road which some powerful interest groups are 
keen to strew with obstacles and diversions. 
 The widespread availability of a relatively inexpensive 
medicine that would be both safe and effective in promoting 
and maintaining weight loss is a holy grail. This will be 
challenging, as it is likely that such a drug or drug combination 
would probably have to be, at least in part, targeted at the 
central nervous system. The brain tends to use identical 
chemical signals to subserve one function in one anatomical 
area and a different function in another. This was the problem 
that caused the withdrawal of rimonabant, an anti-cannabinoid 
drug that powerfully suppressed appetite and promoted weight 
loss, but which unfortunately had anti-hedonic properties that 
promoted suicidal behaviour in some recipients. 67 
 Should we give up? I don’t think so. I believe that using 
hypertension as an analogy is helpful and can put our current 
issues with development of anti-obesity drugs into a historical 
perspective. For the first half of the 20th century, hypertension 
was a major public health problem in many countries, with 
many deaths from renal and cardiac failure and malignant 
hypertension being a common medical emergency. 68 There 
were no effective drugs, and drastic surgical approaches such 
as cervical sympathectomy needed to be undertaken in severe 
cases. Some useful drugs such as trimethaphan, reserpine and 
methyldopa emerged, but all had common and severe side 
effects. Gradually a better understanding of hypertension as a 
disorder of renal sodium retention began to emerge and drugs 
that acted in those processes began to develop. Now we have 
at least four classes of antihypertensive drugs, all of which are 
now generic and cheap and, when used in combination, there 
is almost no one whose blood pressure cannot be satisfactorily 
controlled. These advances in clinical pharmacology have 
been accompanied by public health efforts focused on primary 
prevention through limitation of salt intake. Using such a 
multidisciplinary approach, remarkable advances have been 
made in the prevention and treatment of blood pressure. 68 
Obesity has some striking similarities to hypertension, both 
conditions simply representing terms for the upper ends of 
a continuously distributed trait at which people begin to 
exhibit increased morbidity and mortality. Compared with 
our mature understanding of the control of blood pressure, the 
fundamental science of the control of human body weight is 
still in its infancy. It would seem premature to abandon hopes 
for effective pharmacotherapy for obesity when there is still so 
much to learn and to exploit for the benefit of human health. 
 The consequences of obesity 
 Increasing adiposity is significantly associated with a number 
of causes of morbidity and mortality. Of these some, such 
as osteoarthritis of the knee, obstructive sleep apnoea and 
reflux oesophagitis, are contributed to by the mechanical and 
gravitational effects of an excessive weight and volume of adipose 
tissue. The links of obesity with uterine, breast and bowel 
cancer are statistically robust, but as yet the mechanisms remain 
unclear. 69 One very common disorder where the link with obesity 
is particularly strong is type 2 diabetes. Indeed, much of the 
public health concern surrounding obesity relates to its impact 
on the incidence of type 2 diabetes with all its disabling and 
expensive complications. 70 It is not necessarily intuitively obvious 
why carrying around excess triglycerides in adipose tissue leads 
to a disturbance of carbohydrate metabolism characterised by 
uncontrolled elevation of plasma glucose levels. 
 The first clues as to how these two disorders might be linked 
came shortly after insulin could be measured in the plasma. 
Bierman  et al 71 showed that, in non-diabetic people, there was 
a strong positive correlation between adiposity and fasting 
CMJv16n6-Harveian.indd   556 19/11/16   1:25 PM
Harveian Oration 2016
© Royal College of Physicians 2016. All rights reserved. 557
insulin, ie for any given level of blood glucose, obese people 
needed to make more insulin to maintain normal blood 
glucose. Many subsequent studies, including those using 
more gold-standard measures of insulin action such as the 
euglycaemic hyperinsulinaemic clamp, have confirmed the 
association with obesity and an even stronger association with 
central rather than peripheral fat distribution. 72 Reaven was 
among the first to report that, even among non-diabetic people, 
insulin resistance was often accompanied by a constellation of 
cardiovascular risk factors, including high triglycerides, low 
high-density lipoprotein (HDL) cholesterol and high blood 
pressure, a cluster that has subsequently become known as the 
‘metabolic syndrome’. 73 It is widely accepted that the insulin-
resistant state, which drives a chronic increase of insulin 
secretory activity from the pancreatic beta cell, will – at least 
in susceptible individuals – lead to the eventual ‘exhaustion’ of 
islet function and to the hyperglycaemia that is the diagnostic 
feature of diabetes. 74 
 Thus, obesity is clearly associated with a state of ‘resistance’ to 
the glucose-lowering effects of insulin. How might that happen? 
To understand this, one has to have some understanding of how 
insulin normally controls carbohydrate metabolism. 
 How does insulin normally exert its effect on 
carbohydrate metabolism? 
 It must be remembered that the principal evolutionary purpose 
of having mechanisms for the tight control of circulating 
levels of glucose is largely related to the fact that the brain 
has an absolute requirement for glucose and that even a short 
period of significant hypoglycaemia is extremely deleterious 
to brain function. Thus, the liver is set up as a glucose-
producing factory that, even under conditions of extreme 
and prolonged starvation, can continue to provide the brain 
with glucose (and, as starvation progresses, ketones) at the 
expense of depleting other nutritional resources of the body. 75 
The system that controls blood glucose at its lower levels and 
prevents hypoglycaemia relies on a balance between a range of 
glucose-raising hormones and the rapid suppression of insulin, 
a hormone that has a circulating half-life of only around 
4.5 minutes. 76 At the other end of the normal blood glucose 
excursion, insulin levels rise in response to increasing levels of 
blood glucose in a manner that, in healthy individuals, prevents 
the blood glucose level ever exceeding the renal threshold for 
glucose resorption; this situation would represent a loss of 
calories that, in evolutionary terms, would likely have been 
deleterious. If sustained hyperglycaemia is allowed to persist, 
certainly if it does so for a matter of years, this also leads to 
widespread damage to the endothelium of small blood vessels 
that characterises diabetic retinopathy, neuropathy and 
nephropathy. Thus, understanding how insulin acts to control 
carbohydrate metabolism is critical to the understanding of 
diabetes. 
 Insulin, a peptide hormone produced only by the beta cells of 
the pancreatic islet, signals through a widely expressed dimeric 
transmembrane receptor tyrosine kinase. This acts through 
adaptor molecules to activate phosphatidylinositol 3-kinase, 
which generates a lipid signal, phosphatidylinositol 3-phosphate 
(PIP3), within the plasma membrane. That particular lipid 
avidly binds to a region of the serine/threonine kinase AKT2, 
recruiting it to the plasma membrane, where it is activated. 
Depending on the precise cell type, this initiates a series of 
events that alter the cellular handling of nutrients. 77 In liver 
cells, AKT2 activation triggers a catalogue of changes in post-
translational modification of enzymes and in gene expression, 
which serve to switch off glucose production (gluconeogenesis) 
in the liver and promote glycogen storage in several tissues. In 
skeletal and cardiac muscle (and in adipocytes, which, however, 
in total take up a much smaller proportion of circulating 
glucose than does muscle), insulin’s stimulation of AKT2 has 
an additional impact. It stimulates the rapid translocation 
to the plasma membrane of vesicles containing the glucose 
transporter GLUT4, thus promoting rapid uptake of glucose 
into the tissues expressing this transporter. 78 Tissues such as 
brain and haematopoeitic organs use large amounts of glucose 
but, in those sites, the uptake of glucose is not dependent on 
insulin. 
 The earliest defect discernible in individuals who are insulin 
resistant and ‘pre-diabetic’ appears to be an impaired ability 
of insulin to recruit GLUT4-containing vesicles to the plasma 
membrane in muscle. 79 Only later in the disease is it possible 
to discern that insulin’s suppression of glucose production 
by the liver is also impaired. It is important to point out that 
a pure state of insulin resistance is, alone, seldom enough to 
produce the sustained hyperglycaemia of type 2 diabetes. 80 The 
healthy pancreatic islet has a remarkable ability to upregulate its 
secretion of insulin to compensate for even profound degrees of 
insulin resistance. However, it can rarely do so indefinitely and 
indeed, if it is itself genetically vulnerable, can only do so for 
short periods of time. 
 How does over-nutrition lead to defects in insulin’s 
control of carbohydrate metabolism? 
 The infl ammatory hypothesis 
 One particular hypothesis currently appears to be in the 
ascendant. It derives from the uncontroversial and highly 
replicated observation that the adipose tissue of obese people 
contains an excess of cells primarily involved in immunity and/
or host defence, and shows more evidence of activation of those 
cells than does adipose tissue from lean people. 81 
 Supporting the importance of these observations is the 
undoubted finding that infusion of a range of cytokines 
into animals can make them insulin resistant; an even more 
compelling set of observations shows that the link between 
obesity and insulin resistance can be interfered with by genetic 
manipulations, which secretively disable a range of signalling 
pathways specifically within macrophages and other cells of the 
immune/host defence system. 82 However, the evidence that this 
work translates to humans is, at present, rather less convincing. 
Indeed, to date there is little published evidence that the use of 
non-specific 83 or specific 84 anti-inflammatory agents has any 
sustained, significant impact on human insulin sensitivity. 
 Numerous genetic variants influencing the expression of 
cytokine molecules or their receptors exist in the human 
genome and many of these significantly and reproducibly 
influence the risk of a range of diseases that are known 
to have an inflammatory or autoimmune basis. 85 While 
there is extensive overlap between a wide range of common 
inflammatory diseases in terms of common genetic variants 
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and the cells and tissues in which such variants are thought 
likely to act, there is little overlap or shared features of 
inflammatory disease with metabolic disease 85 or indeed 
with adiposity. 86 The ongoing absence of convincing human 
pharmacological or genetic evidence to support the relevance 
of the inflammation hypothesis in humans suggests that we 
must continue to look elsewhere for alternative mechanistic 
explanations for the link between human over-nutrition and 
impaired insulin action. 
 An alternative hypothesis: insulin resistance occurs when 
the adipose depot is no longer able to safely store all excess 
energy, and other tissues are subjected to macronutrient 
overload 
 We know that exposing either liver or skeletal muscle cells,  in 
vitro or  in vivo , to an acute overload of nutrients, particularly in 
the form of free fatty acid, consistently impairs insulin’s ability 
to influence glucose metabolism, 87,88 including impairing 
GLUT4 translocation in skeletal muscle, the earliest discernible 
abnormality of insulin action in people on their way to 
developing type 2 diabetes. 79 Obesity is, by definition, a state 
of overprovision of calories in relation to energy expenditure. 
But we have professional cells, the adipocytes, designed to 
detect any such excess of ingested nutrients and lay them down 
for a rainy day. What if this storage depot did not function 
properly, either through being inadequate in size or defective 
in function? The excess ingested nutrients would have to be 
dealt with somewhere. This is not just a thought experiment; 
this is what happens in a range of human conditions called 
lipodystrophies. 
 A lipodystrophy is a condition characterised by an inherent 
inability to make fat cells or to synthesise triglycerides within 
fat cells. 89 It can be caused by genetic defects impairing 
adipocyte differentiation or triglyceride synthesis, or by 
destruction of fat cells and their precursors by autoimmune 
mechanisms. It is increasingly recognised, at least in a partial 
form, as a consequence of total body irradiation for certain 
childhood cancers, 90 and of chronic antiviral therapy for 
HIV infection. 91 What characterises all generalised forms of 
lipodystrophy, whatever their causes, is the early development 
of insulin resistance, dyslipidaemia and fatty liver reminiscent 
of an aggressive version of more typical ‘metabolic syndrome’. 
Indeed, there is no feature of the metabolic syndrome, 
including increased risks of atherosclerosis and severe fatty 
liver disease, that is not reliably present in patients with 
lipodystrophy. Of course, in cases where no adipose tissue is 
present, the cause of the insulin resistance cannot be ascribed to 
inflammation in an adipose depot that simply isn’t there. 
 A few years ago, in work led by my colleague David Savage 
with colleagues in Paris, we described a new form of human 
lipodystrophy, which, although rare, I believe to be particularly 
illuminating (Fig  3 ). Affected individuals had diminished, but 
not absent, fat cell mass and were afflicted with every feature 
of the metabolic syndrome from an early age. They carried 
one of two different heterozygous frameshift mutations within 
the perilipin 1 gene that resulted in retention and continued 
expression of the molecule’s normal N-terminal portion, but a 
structural disruption of its C-terminal region. 92,93 Perilipin 1 is 
a protein expressed only in white adipocytes, where it coats the 
large unilocular triglyceride droplet unique to that cell type. 
At the location, it serves a crucial regulatory role. When we 
are in a fed state, we have no need to access the energy stored 
in our adipocyte triglyceride droplet and, in these conditions, 
perilipin 1 acts as its guardian. It binds a protein called CGI58 
tightly to its C-terminus. When allowed to roam free, CGI58 
zips around the surface of the droplet, binding tightly to the 
enzyme adipose triglyceride lipase (ATGL), which initiates the 
cascade of triglyceride breakdown. The N-terminus of perilipin 
1 plays an important role in continuing the lipolytic cascade by 
attracting hormone-sensitive lipase (HSL), which hydrolyses 
diglycerides, to the surface of the droplet. Thus, in the fasting 
state, signalling cascades in the fat cell result in phosphorylation 
of the C-terminus of perilipin 1, freeing CGI58 to bring ATGL 
to the droplet to initiate the process of triglyceride breakdown 
and also phosphorylating the N-terminus to attract HSL, which 
performs the second step. In the patients with one mutant copy 
of perilipin 1, there is always a component of CGI58 which 
is free to continually bring ATGL to the droplet and drive 
continuing fat droplet breakdown, even during the fed state. 
Remarkably, this subtle disturbance affecting only the white 
fat cell and, within that cell, only impacting on the control 
of lipolysis on the surface of the lipid droplet, is sufficient to 
result in every feature of the metabolic syndrome in patients 
carrying this form of defective allele. Although very rare, this 
syndrome provides a compelling model whereby a relatively 
subtle disturbance of the lipid storage function of the fat cell, 
which is itself not a major quantitatively important site for 
glucose disposal in the whole organism, is sufficient, alone, to 
cause severe insulin resistance and all its associated pathologies 
in humans. 
 Might such mechanisms be relevant in common forms of 
insulin resistance? It has certainly been suggested by several 
investigators that impaired adipose storage capacity and 
lipid overflow may have broad importance; 94–96 however, it 
has been challenging to obtain any reliable estimates of the 
extent to which it might be responsible for insulin resistance 
in the general human population. We have recently worked 
with colleagues in the MRC Epidemiology Unit within our 
institute to test this hypothesis more robustly. 97 We first 
examined genetic and phenotypic data from more than 150,000 
people to identify genetic variants that were associated with a 
‘triad’ of elevated BMI-adjusted fasting insulin, higher serum 
triglycerides and low serum HDL cholesterol, and identified 
53 SNPs that were replicably associated with these measures 
(as well as with type 2 diabetes and cardiovascular disease in 
independent analyses). 
 Remarkably, when studied in independent cohorts in whom 
regional fat distribution had been measured by DEXA, the 
strongest association of the combined 53 SNP genetic risk score 
was not with an increase in central or visceral fat as might have 
been expected, but with a marked reduction in femoral and 
gluteal fat. The importance of adipose tissue genes in mediating 
this phenotype was supported by the 53 loci containing genes 
highly expressed in adipose tissue and substantial overlap 
with adipose tissue-active enhancer elements, as well as by 
functional analysis of adipocytes in which several of the 
novel genes had been disrupted. In summary, a hypothesis-
free analysis looking for genetic variants that predispose to 
‘metabolic syndrome’ revealed a set of variants that are strongly 
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implicated as affecting adipose tissue and that impair its 
ability to differentiate, and expand. It would seem reasonable 
to conclude that a ‘  forme fruste ’ of lipodystrophy is a major 




















































































 Fig 3.  Coordination of the control of triglyceride breakdown on the surface of the adipocyte fat droplet in the fasting and fed state in a healthy 
individual (A) and in a patient with a mutation disrupting the C-terminus of perilipin 1 (B) . In the fasting state, perilipin 1 (P1), a protein that sits 
on the surface of the triglyceride droplet of the fat cell, is phosphorylated near its C-terminus. This prevents it from binding CGI58 and allows the latter to 
bind and activate adipocyte triglyceride lipase (ATGL), the enzyme that initiates triglyceride breakdown. The diglycerides formed by this reaction are broken 
down by hormone-sensitive lipase (HSL), the active phosphorylated form of which binds to perilipin 1 when the latter is phosphorylated at a residue close to 
its N-terminus. Monoglyceride lipase (MGL) is constitutively active. Thus, in the fasting state, the fat cell effi ciently releases abundant free fatty acid into the 
systemic circulation for use by other organs. In the fed state, perilipin 1 is dephosphorylated and binds tightly to CGI58, preventing it from interacting with 
and activating ATGL; HSL does not interact with dephosphorylated perilipin 1 and thus the process of adipocyte lipolysis is effi ciently shut down in the fed 
state while triglyceride synthesis is activated, with free fatty acids derived from triglycerides delivered to the fat tissue in lipoproteins generated in the gut and 
the liver, with lesser amounts coming from re-esterifi cation and from de novo lipogenesis in fat. Patients with mutations that disrupt the C-terminal phosphory-
lation site of a single copy of their perilipin 1 protein have a syndrome characterised by all the features of the metabolic syndrome in the face of a diminished, 
but not absent, fat cell mass. This occurs because the mutant C-terminal tail of perilipin 1 is unable to bind CGI58 so, even in the fed state, ATGL remains at 
the lipid droplet surface and active; thus, free fatty acids are generated from the adipocyte irrespective of the nutritional state. That disruption of lipid droplet 
triglyceride regulation is suffi cient, alone, to result in every feature of the metabolic syndrome. ATGL = adipocyte triglyceride lipase; C = C-terminus of perilipin 
1; DG = diglyceride; FA = fatty acid; FFA = free fatty acid; HSL = hormone-sensitive lipase; LPL = lipoprotein lipase; MG = monoglyceride; MGL = monoglyceride 
lipase; N = N-terminus of perilipin 1; P1 = perilipin 1; TG = triglyceride 
societies where over-nutrition is widespread. In simple terms, 
those who are able to greatly expand their adipose mass in 
the face of chronic over-nutrition can avoid insulin resistance 
and metabolic syndrome, while those who have continued 
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imbalance of energy input over expenditure but are unable to 
safely store this in adipose tissue are the people who will suffer 
the most severe metabolic derangements (Fig  4 ). 
 Orthogonal evidence supporting the ‘nutritional’ rather than 
the ‘inflammatory’ hypothesis has come from recent elegant 
(and heroic) studies from Boden and colleagues, who clearly 
showed how marked insulin resistance could be induced by just 
a few days of severe caloric overload at a stage when there was 
no evidence of increased inflammation, or indeed endoplasmic 
reticulum (ER) stress, in fat or muscle biopsies. 98 
 It is somewhat ironic that it was actually our laboratory 
that made the first published observations showing that a 
macrophage product was more highly expressed in fat from 
obese than from lean humans. 99 We didn’t make much of this 
at the time, as we thought it likely to reflect a higher rate of 
cell death in overloaded adipose tissue, a supposition that was 
subsequently elegantly confirmed by Cinti  et al . 100 
 The primacy of pancreatic beta cell dysfunction 
in determining the onset of hyperglycaemia 
 Recent large-scale, genome-wide studies comparing patients 
with type 2 diabetes and controls have identified multiple 
associated loci, 101 the majority of which are implicated in 
insulin secretory capacity rather than insulin sensitivity. 102 
This is consistent with the fact that the vast majority of 
single gene disorders causing diabetes do so by impairing 
the function of the pancreatic beta cell. 103 It seems clear 
that, despite the fact that over-nutrition leads to insulin 
resistance and this is likely to be playing a key role in driving 
the epidemic of type 2 diabetes, it is the intrinsic health of 
the islet that ultimately determines whether a person remains 
hyperinsulinaemic but does not develop hyperglycaemia or 
whether type 2 diabetes ensues. Of course insulin-resistant, 
hyperinsulinaemic individuals may have all the other 
features of the metabolic syndrome, including higher risk of 
macrovascular disease, but will not develop the microvascular 
complications of retinopathy, nephropathy and neuropathy 
unless hyperglycaemia occurs. I have gained some personal 
satisfaction from these recent genetic discoveries, as work I had 
undertaken at the beginning of my scientific career, in the lab of 
the late Professor Robert Turner in Oxford, demonstrated that 
quantitative 104 and qualitative 105 defects of insulin secretion 
were detectable in first-degree relatives of patients with type 2 
diabetes long before they developed diabetes. 
 Do these findings have any direct relevance 
for patient care or public policy? 
 Caloric restriction is a keystone of type 2 diabetes therapy. 
Its efficacy has been known since the Allen diets 106 at the 
beginning of the last century and is rediscovered every few 
decades or so. 107,108 The model whereby individuals develop 
lipotoxicity in organs such as liver and muscle (and possibly 
pancreas) when they reach the limits of safe energy storage 
in adipose tissue provides a useful explanation for the rapid 
improvement in glycaemic control occurring long before any 
significant loss of weight or indeed cellular composition of 
adipose tissue, and also why different individuals develop 
insulin resistance at different levels of adiposity. The key 
challenge is the fact that caloric restriction is very hard for 
most people to maintain in the long term, as the drive to eat is 
enhanced by changes in hormonal milieu that tend to drive the 
weight back towards its starting point. 109 Bariatric surgery is so 
remarkably effective in diabetes because it provides an ongoing 
and sustained signal to reduce food intake and therefore 
maintain a healthy energy balance. 66 
 The idea of ‘safe fat’ may seem paradoxical, given the 
epidemiological relationship between BMI and insulin 
resistance, but there is a large amount of variation around that 
distribution and many obese people, particularly those with 
large gluteofemoral subcutaneous depots, remain remarkably 
healthy. Of note, thiazolidinedione drugs, which are among 
the most potent insulin sensitisers, appear to sensitise to a 
substantial extent by promoting adipocyte differentiation 
and increasing ‘safe’ triglyceride storage in adipose tissue. 110 
Conversely, it would appear that pursuing anti-inflammatory 
strategies may not be a highly effective way of interrupting the 
link between obesity and insulin resistance. 
 There are many populations worldwide with high risks of 
type 2 diabetes, even though they have generally lower levels 
of adiposity than those seen in the west. It will be fascinating 
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A    Healthy B    Obese insulin resistant C    Non-obese insulin resistant
Adipose storage capacity
Adipocyte stored triglyceride
 Fig 4.  The ‘soggy bathroom carpet’ model of over-nutrition-related metabolic disease . A – In health, chronic energy intake (the fl ow through the tap) 
is matched by energy expenditure (the fl ow through the open plughole) such that there is a moderate but healthy amount of excess energy stored (the water 
rises, but does not overfl ow the bathtub). B – In an individual with marked obesity that has led to diabetes, the energy infl ow chronically exceeds the energy 
outfl ow such that the amount of stored energy exceeds the capacity to safely store it and excess nutrients fl ow elsewhere, causing damage (the soggy carpet). 
C – In individuals with a limited ability to expand adipose tissue storage capacity (a smaller bathtub), even a small excess of energy intake over expenditure will 
lead to energy being misdirected (overfl owing the bathtub) and to adverse metabolic outcomes including fatty liver, insulin resistance and diabetes. 
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to find out whether people from those groups have an intrinsic 
limitation in the generation of new fat cells and whether that 
relates to genetics or to early life events. Indeed, if the early 
nutritional environment did indeed somehow ‘programme’ 
the stem cells from which adipocytes are derived and limit the 
number of subcutaneous adipocytes that could be recruited 
to cope with later over-nutrition, this could be an important 
target for early pre and postnatal nutritional interventions. It is 
tempting to reflect, as others have done previously, 111 that the 
particular susceptibility of ethnic groups such as south Asians 
to develop insulin resistance and diabetes might have a related 
mechanism. 
 Conclusions 
 Much of what we have learned about the control of human body 
weight and insulin sensitivity and secretion has come, not from 
the study of patients with common complex forms of disease, 
but from the identification of rare individuals with precise 
single gene defects where one can unequivocally trace the causal 
chain of pathogenesis. Even in conditions as common as obesity 
and type 2 diabetes, insights into disease mechanisms can come 
from the careful characterisation of such human ‘experiments 
of nature’. This has been a recurrent theme of Harveian 
Orations, including those from Archibald Garrod (1924)  The 
debt of science to medicine , 112 David Weatherall (1992)  The role 
of nature and nurture in common diseases: Garrod’s legacy 113 
and Keith Peters (2004)  Exceptional matters . 114 The power and 
reach of this approach will probably increase as comprehensive 
genomic interrogation of individual unusual patients becomes 
more routine. 
 Endocrine and metabolic disorders are quintessentially 
disorders of communication across the whole organism and 
cannot be understood solely by the study of isolated cells. The 
function and nature of leptin (or, for that matter, insulin) 
would never have been discovered in a culture dish. We need to 
recognise how important studies undertaken in animals have 
been to this and other fields. While we should study humans 
wherever possible, we will be unable, for example, to understand 
issues related to the sites of action of hormone action without 
using rodent models in which we can alter gene expression 
and function in a tissue-specific and/or temporally controlled 
fashion. We must study animals sparingly and compassionately, 
but the advance of science and medicine will, for the foreseeable 
future, remain highly dependent on such studies. 
 Returning to the patient with whom I began this lecture, what 
can we offer patient M? What she clearly needs is a procedure 
that permanently reduces her drive to eat and renders her 
persistently and substantially leaner than her body ‘wants to 
be’. Only that way will we ‘unload’ the nutrient excess that is 
overwhelming her limited capability to lay down safe fat stores. 
The beneficial effects of bariatric surgery on diabetes are often 
dramatic and are not even restricted to those who are formally 
obese. 
 There are increasing reports of lipodystrophic patients 
whose severe insulin resistance and poorly controlled diabetes 
are effectively cured as a result of surgery. 115 This is not that 
surprising if one considers the mechanisms of lipid overflow 
and lipotoxicity associated with limited safe fat storage capacity, 
discussed in detail earlier in this lecture. Unfortunately for M, 
the UK lags far behind most advanced countries in the provision 
of ‘metabolic surgery’ 116 and she will probably face many barriers 
to accessing this highly successful treatment. 117 The National 
Institute for Health and Care Excellence (NICE) has recently 
published a quality standard for the clinical assessment and 
management of obesity, 118 which includes the explicit recognition 
of the important role that bariatric surgery plays. It is to be hoped 
that this will lead to a marked change in behaviour of health 
commissioners and providers, so that this highly cost-effective 
form of care can be delivered to patients such as M. 
 I believe that there are grounds for optimism, that we 
can reduce the human suffering, disability and early death 
resulting from the medical consequences of over-nutrition, 
much as we have done to reduce the adverse outcomes 
resulting from the sustained elevation of blood pressure. 
Interventions that usefully render our environment less 
obesogenic will require sustained lobbying until the necessary 
courageous political decisions are made. The burgeoning basic 
science of energy balance and metabolism will uncover novel 
therapeutic targets and pathways with exciting opportunities 
for improved drugs and devices, which may be combined with 
better subclassification of the ‘obesities’ and more effective 
targeted therapeutics. However, progress is threatened by 
the fact that, despite the global importance of obesity as a 
threat to public health, expenditure on research in metabolic 
disorders is only a small fraction of that spent on, for example, 
cancer or heart disease. Where obesity and hypertension 
differ most strikingly is in the degree to which they are 
stigmatised. A person’s high blood pressure is not obvious 
to others and few people attribute hypertension to the fault 
of the individual. A person’s severe obesity is all too obvious 
to casual observers, many of whom are prone to attributing 
the condition solely to personal failing. This commonly held 
view has contributed to widespread social and economic 
discrimination against people who are obese 119,120 and to our 
reluctance to provide effective therapies, even when they are 
available and cost-effective. As the science of human obesity 
continues to advance, such views will increasingly be seen as 
illogical and unsupportable. ■
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